$2.97 Billion is the total value of Vident Investment Advisory, LLC's 987 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MGNX | MACROGENICS INC | $2,293,000 | +39.3% | 71,987 | 0.0% | 0.08% | +14.9% | |
| ALLO | ALLOGENE THERAPEUTICS INC | $2,103,000 | +39.9% | 59,564 | 0.0% | 0.07% | +16.4% | |
| SRRK | SCHOLAR ROCK HLDG CORP | $1,731,000 | +4.4% | 34,170 | 0.0% | 0.06% | -14.7% | |
| DPZ | DOMINOS PIZZA INC | $1,645,000 | -4.1% | 4,472 | 0.0% | 0.06% | -21.4% | |
| XNCR | XENCOR INC | $1,640,000 | -1.3% | 38,092 | 0.0% | 0.06% | -19.1% | |
| ARGX | ARGENX SEsponsored adr | $1,585,000 | -6.3% | 5,754 | 0.0% | 0.05% | -23.2% | |
| GMAB | GENMAB A/Ssponsored ads | $1,381,000 | -19.2% | 42,053 | 0.0% | 0.05% | -34.3% | |
| MOR | MORPHOSYS AGsponsored ads | $1,282,000 | -23.1% | 58,814 | 0.0% | 0.04% | -36.8% | |
| BLUE | BLUEBIRD BIO INC | $1,156,000 | -30.3% | 38,333 | 0.0% | 0.04% | -42.6% | |
| ALXO | ALX ONCOLOGY HLDGS INC | $1,074,000 | -14.5% | 14,571 | 0.0% | 0.04% | -29.4% | |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | $1,045,000 | -31.8% | 33,008 | 0.0% | 0.04% | -43.5% | |
| ZYME | ZYMEWORKS INC | $984,000 | -33.2% | 31,168 | 0.0% | 0.03% | -45.0% | |
| YMAB | Y-MABS THERAPEUTICS INC | $951,000 | -38.9% | 31,439 | 0.0% | 0.03% | -49.2% | |
| TX | TERNIUM SAsponsored ads | $777,000 | +33.5% | 20,000 | 0.0% | 0.03% | +8.3% | |
| NKTX | NKARTA INC | $750,000 | -46.5% | 22,800 | 0.0% | 0.02% | -56.1% | |
| TNDM | TANDEM DIABETES CARE INC | $441,000 | -7.7% | 5,000 | 0.0% | 0.02% | -21.1% | |
| BMO | BANK MONTREAL QUE | $288,000 | +17.6% | 3,231 | 0.0% | 0.01% | 0.0% | |
| BNS | BANK NOVA SCOTIA B C | $290,000 | +17.4% | 4,642 | 0.0% | 0.01% | 0.0% | |
| RCI | ROGERS COMMUNICATIONS INCcl b | $232,000 | -0.9% | 5,026 | 0.0% | 0.01% | -20.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NVIDIA CORPORATION | 35 | Q2 2023 | 1.8% |
| UNITEDHEALTH GROUP INC | 35 | Q2 2023 | 1.0% |
| MICROSOFT CORP | 35 | Q2 2023 | 1.2% |
| ELEVANCE HEALTH INC | 35 | Q2 2023 | 0.6% |
| AMGEN INC | 35 | Q2 2023 | 0.7% |
| AT&T INC | 35 | Q2 2023 | 0.7% |
| WAL-MART STORES INC | 35 | Q2 2023 | 0.8% |
| MERCK & CO INC NEW | 35 | Q2 2023 | 1.0% |
| BRISTOL-MYERS SQUIBB CO | 35 | Q2 2023 | 0.4% |
| QUEST DIAGNOSTICS INC | 35 | Q2 2023 | 0.4% |
View Vident Investment Advisory, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-12 |
| 40-APP | 2021-11-10 |
View Vident Investment Advisory, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.